Melbourne-based Telix Pharmaceuticals (ASX:TLX) has reached a pivotal regulatory milestone with the US Food and Drug Administration accepting its resubmitted New Drug Application for TLX101-Px, trade-named Pixclara.
The investigational positron emission tomography agent, also known as 'Floretyrosine F18' (18F-FET), is designed to revolutionise the imaging of glioma, a challenging form of brain cancer, in both adult and paediatric patients.
The FDA has assigned a PDUFA goal date of Sept. 11, marking a definitive timeline for the potential commercialisation of a tool that addresses a critical "unmet medical need".
Currently, clinicians struggle to distinguish between recurrent tumour progression and treatment-related changes, such as inflammation or necrosis caused by radiation.
Pixclara targets specific membrane transport proteins, allowing for clearer characterisation of the disease where standard imaging often proves ambiguous.
Medical experts from UCSF and Mass General Brigham have lauded the acceptance, noting that while 18F-FET imaging is already recommended by international guidelines (including the NCCN), FDA approval would finally provide broad access for American clinicians.
Despite the high stakes, Telix has maintained a conservative fiscal stance, confirming that its FY26 financial guidance does not yet include revenue contributions from the product.